1
|
Discovery of Selective Butyrylcholinesterase (BChE) Inhibitors through a Combination of Computational Studies and Biological Evaluations. Molecules 2019; 24:molecules24234217. [PMID: 31757047 PMCID: PMC6930573 DOI: 10.3390/molecules24234217] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2019] [Revised: 11/14/2019] [Accepted: 11/17/2019] [Indexed: 11/17/2022] Open
Abstract
As there are increased levels and activity of butyrylcholiesterase (BChE) in the late stage of Alzheimer’s disease (AD), development of selective BChE inhibitors is of vital importance. In this study, a workflow combining computational technologies and biological assays were implemented to identify selective BChE inhibitors with new chemical scaffolds. In particular, a pharmacophore model served as a 3D search query to screen three compound collections containing 3.0 million compounds. Molecular docking and cluster analysis were performed to increase the efficiency and accuracy of virtual screening. Finally, 15 compounds were retained for biological investigation. Results revealed that compounds 8 and 18 could potently and highly selectively inhibit BChE activities (IC50 values < 10 μM on human BChE, selectivity index BChE > 30). These active compounds with novel scaffolds provided us with a good starting point to further design potent and selective BChE inhibitors, which may be beneficial for the treatment of AD.
Collapse
|
2
|
Kantham S, Chan S, McColl G, Miles JA, Veliyath SK, Deora GS, Dighe SN, Khabbazi S, Parat MO, Ross BP. Effect of the Biphenyl Neolignan Honokiol on Aβ 42-Induced Toxicity in Caenorhabditis elegans, Aβ 42 Fibrillation, Cholinesterase Activity, DPPH Radicals, and Iron(II) Chelation. ACS Chem Neurosci 2017. [PMID: 28650631 DOI: 10.1021/acschemneuro.7b00071] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
The biphenyl neolignan honokiol is a neuroprotectant which has been proposed as a treatment for central nervous system disorders such as Alzheimer's disease (AD). The death of cholinergic neurons in AD is attributed to multiple factors, including accumulation and fibrillation of amyloid beta peptide (Aβ) within the brain; metal ion toxicity; and oxidative stress. In this study, we used a transgenic Caenorhabditis elegans model expressing full length Aβ42 as a convenient in vivo system for examining the effect of honokiol against Aβ-induced toxicity. Furthermore, honokiol was evaluated for its ability to inhibit Aβ42 oligomerization and fibrillation; inhibit acetylcholinesterase and butyrylcholinesterase; scavenge 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals; and chelate iron(II). Honokiol displayed activity similar to that of resveratrol and (-)-epigallocatechin gallate (EGCG) in delaying Aβ42-induced paralysis in C. elegans, and it exhibited moderate-to-weak ability to inhibit Aβ42 on-pathway aggregation, inhibit cholinesterases, scavenge DPPH radicals, and chelate iron(II). Moreover, honokiol was found to be chemically stable relative to EGCG, which was highly unstable. Together with its good drug-likeness and brain availability, these results suggest that honokiol may be amenable to drug development and that the synthesis of honokiol analogues to optimize these properties should be considered.
Collapse
Affiliation(s)
- Srinivas Kantham
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Stephen Chan
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Gawain McColl
- The
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Jared A. Miles
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Suresh Kumar Veliyath
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Girdhar Singh Deora
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Satish N. Dighe
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Samira Khabbazi
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Marie-Odile Parat
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Benjamin P. Ross
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| |
Collapse
|
3
|
Belinskaia DA, Taborskaya KI, Avdonin PV, Goncharov NV. Modulation of the albumin–paraoxon interaction sites by fatty acids: Analysis by the molecular modeling methods. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2017. [DOI: 10.1134/s1068162017030037] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
4
|
Dighe SN, Deora GS, De la Mora E, Nachon F, Chan S, Parat MO, Brazzolotto X, Ross BP. Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening. J Med Chem 2016; 59:7683-9. [PMID: 27405689 DOI: 10.1021/acs.jmedchem.6b00356] [Citation(s) in RCA: 110] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Structure-based virtual screening of two libraries containing 567 981 molecules was used to discover novel, selective BuChE inhibitors, which are potentially superior symptomatic treatments in late-stage Alzheimer's disease. Compound 16 was identified as a highly selective submicromolar inhibitor of BuChE (huBuChE IC50 = 0.443 μM) with high permeability in the PAMPA-BBB model. The X-ray crystal structure of huBuChE in complex with 16 revealed the atomic-level interactions and offers opportunities for further development of the series.
Collapse
Affiliation(s)
- Satish N Dighe
- School of Pharmacy, The University of Queensland , Brisbane, Queensland 4072, Australia
| | - Girdhar Singh Deora
- School of Pharmacy, The University of Queensland , Brisbane, Queensland 4072, Australia
| | - Eugenio De la Mora
- Institut de Biologie Structurale (IBS), Université Grenoble Alpes, CEA, CNRS, 38044 Grenoble, France
| | - Florian Nachon
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées , 91223 Brétigny sur Orge, France
| | - Stephen Chan
- School of Pharmacy, The University of Queensland , Brisbane, Queensland 4072, Australia
| | - Marie-Odile Parat
- School of Pharmacy, The University of Queensland , Brisbane, Queensland 4072, Australia
| | - Xavier Brazzolotto
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées , 91223 Brétigny sur Orge, France
| | - Benjamin P Ross
- School of Pharmacy, The University of Queensland , Brisbane, Queensland 4072, Australia
| |
Collapse
|
5
|
Belinskaya DA, Shmurak VI, Prokofieva DS, Goncharov NV. Serum albumin: Search for new sites of interaction with organophosphorus compounds by the example of soman. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2014. [DOI: 10.1134/s1068162014050033] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|